In this week's US stock market, a stock called Summit Pharmaceuticals (SMMT) emerged as a rising force. In addition to its own 160% surge, it also pulled up biotech companies such as BioNTech and Instil Bio. Since the beginning of the year, Summit Pharmaceuticals has risen from less than $3 to $31.93 at the end of this week, with a staggering increase of 1123.37%, and its market value has risen to $23.1 billion. Behind this, in addition to the common benefits of new drug development, there is also a story of China US cooperation.